The industry is on the cusp of delivering a new age of healthcare and will need capital. Can it retain its idealism through that process?
Follow the sector closely and youll start to notice an underlying theme in the new age of psychedelics a deep-rooted ambition to do good for others. Not every industry is able to deliver on that promise, but the business of psychedelics wants to be different.
Although 2020 served as a launching pad for psychedelics investing, decades of work and activism have gone largely unnoticed by players in the capital markets.
Now that theres money to be made and lots of it by even the most conservative estimates investors will have to grapple with the altruistic interests of the players shaping the industry. Those same players may have to get accustomed to the realities of the capital markets.
In the pursuit of capital for such a compassionate industry, which interests will win out? One industry insider believes it could be possible to have both.
Liana Gillooly is a development officer at the Multidisciplinary Association for Psychedelic Studies (MAPS), a research group working on one of the most advanced drug development studies for a psychedelic substance. MAPS is investigating the use of MDMA as a method of psychotherapy for patients with PTSD.
In 2017, this psychedelics-based method was granted a breakthrough therapy designation by the US Food and Drug Administration in a move that represented the drug authoritys changing perspective. MAPS has said in the past that it expects its Phase 3 trials sometime in 2021.
Gillooly told the Investing News Network (INN) that existential questions about how a business and its purpose can help the world at large arent so radical anymore, and psychedelics can help push that even further without compromising capital needs.
The expert is no newcomer to the investment landscape, especially drug-related businesses. Gillooly previously worked with the Arcview Group, a cannabis policy advocacy group and investment network.
The group tracks and advocates for the legalization of cannabis across jurisdictions. But while noble in its intention, the experience of trying to push the social awareness platform into the cannabis investment space eventuallybegan to feel hollow for Gillooly.
I started feeling like our words were empty, because I was looking around the industry and I was seeing that a certain demographic of people was making cash hand over fist, millions of dollars, while another demographic of people was still serving time behind bars for minor cannabis offenses, she said.
The legalization trend for cannabis has highlighted the disparity in opportunities the industry has brought. A report from Vice on a recent study shows white men represent the leading demographic in cannabis companies leadership positions. The studys findings echo a report from the Financial Post showing an absence of minorities in leadership positions in the space.
Gillooly said the stakes are even higher when it comes to social responsibility for the psychedelics industry, since these drugs, if approved, will likely become part of a patients life.
I think the set and setting and the context from which these medicines are received matters, not just, you know, in the immediate environment, but the cultural context. I think it really impacts what a person can get out of these experiences, she noted.
When asked about the entrance of parties interested in psychedelics only for the potential end-game gains, Gillooly recognized that this is already happening in Canada.
She also pointed out that when it comes to the growth factor for the psychedelics stock market, there are very few legitimate opportunities at the moment since the trend is heading towards drug development.
In a previous interview with INN, Richard Carleton, CEO of the Canadian Securities Exchange, said investors should be realistic about the time proposition attached to the investment story of psychedelics.
Even so, the welcoming nature of the Canadian markets has attracted a new rush of listings from various companies trying to capture the attention of investors interested in the psychedelics business proposal.
While Gillooly said this natural, she thinks a critical few are capable of dictating the path for this industry.
I do think that theres enough people and theres enough entrepreneurs and enough funders that recognize that this is a really precious and critical moment and opportunity, and are genuinely desiring to put their money where their mouth is, and to be a little bit more experimental and to see what we can make happen, she said.
I dont think we need everyone, I just think we need a critical mass of people to do that.
Why is psychedelics raising these questions more than other industries?
Saad Shah, managing partner with Noetic Psychedelics, thinks its because the psychedelics business is uniquely positioned to directly help peoples mental health. Thats the main purpose put forth by those directly involved in the sector.
JR Rahn, co-founder and co-CEO of Mind Medicine (MindMed) (NEO:MMED,OTCQB:MMEDF), previously told INN he wants to see this industry completely change the approach to mental health.
Watch the full interview with Rahn above.
MindMed was one of the first firms to publicly listbased on the psychedelics business proposition.
The industry, which has seen a steady rush of new listings and existing public companies rejigging their approaches to pursue opportunities in psychedelics, has received votes of confidence from significant investors with large sway on the motivation of investors.
Arguably chief among them is Shark Tank investor Kevin OLeary. The celebrity businessman politician hasnt shied away from his support of psychedelics with the public launch of MindMed back in February.
Since then, OLeary has continued to voice his enthusiasm for the investment possibility with psychedelics. Most recently he re-emphasized his opinion via Business Insider.
Such high-profile connections have only added to questions about how an industry based on grassroots activism can deal with heavy interest from commercial and investment opportunities as they bubble up.
This discussion recently reached one of the leading drug policy events. At the latest edition of the online Prohibition Partners LIVE event, a panel featuring non-profit psychedelics experts expressed hesitation about the general idea of commercializing plant-based medicines.
The panelists were skeptical about who benefits from introducing commercial concepts to an industry otherwise known for grassroots activism.
Dr. Victoria Hale, a board director for MAPS, said the industry has to be careful and conscientious as commercial interest is only set to grow from hereon out.
The possible benefit of commercialization is broader access, and I think we all would agree that there are many people in the world who would benefit from these medicines, Dr. Hale said.
Alongside the interest from the capital markets comes the question of if that level of attention will affect the focus or direction of the psychedelics industry. One industry observer with plenty of experience in the cannabis space doesnt think so.
Stephen Murphy, co-founder and managing director of drug research firm Prohibition Partners, said capital interest doesnt necessarily mean there isnt an inherent desire to help people otherwise, he said, Theres money to be made in gold and oil and 1,001 other areas.
Prohibition Partners prepares and publishes market insights on the global cannabis industry and has been taking a closer look at the rise of psychedelics, issuing its first report earlier this year.
I think it is the challenge of psychedelics that is attracting a lot of interest, Murphy told INN. There is more information on this now more than ever, yet its just getting the light of day, which is why I think we are seeing this wave of interest.
Murphy called on investors to ask smarter questions when it comes to this sector and for those at the management level at companies in the space to get psychedelics into the mainstream in a responsible and ethical way.
While its clear the psychedelics industry will have to grapple with continued interest from the investment community, one investment group partner previously told INN hes hoping for a marketplace focused on principles and doing good for others.
I think the interesting thing about these substances is that beyond the obvious therapeutic and medical applications that were seeing, I think on a personal level they have this kind of tremendous capacity to (create) personal development and empathy, said Michael Hoyos, co-founding partner, Americas, with the Conscious Fund.
I think thats helped a lot of folks that Ive spoken to feel almost like a certain responsibility to help this industry flourish and develop in the right way.
Dont forget to follow us@INN_LifeSciencefor real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Read the original here:
As Psychedelics Go Mainstream, Can the Industry Keep its Heart? | INN - Investing News Network
- 8 Mystical Herbs and Legal Psychedelics For Lucid Dreaming - December 8th, 2016 [December 8th, 2016]
- Psychedelics: LSD, Mushrooms, Salvia | Facts | Drug Policy ... - December 10th, 2016 [December 10th, 2016]
- FS Book Company - Marijuana Books - December 12th, 2016 [December 12th, 2016]
- Psychedelic - PsychonautWiki - December 27th, 2016 [December 27th, 2016]
- From Alzheimer's To Psychedelics, 2016 Was A Good Year For ... - January 3rd, 2017 [January 3rd, 2017]
- LSD - Psychedelic Effects - The Good Drugs Guide - January 5th, 2017 [January 5th, 2017]
- THC - Psychedelics - January 29th, 2017 [January 29th, 2017]
- Psychedelics | Pharmacological Reviews - January 30th, 2017 [January 30th, 2017]
- Dorian Yates reveals all on steroids, body dysmorphia, psychedelics, cannabis and yoga - Express.co.uk - February 7th, 2017 [February 7th, 2017]
- Psychedelic drug therapy including magic mushrooms, LSD and ... - CBS News - February 7th, 2017 [February 7th, 2017]
- Psychedelics Being Tested For Use In Treating Various Conditions - CBS Local - February 8th, 2017 [February 8th, 2017]
- The psychedelic renaissance - Boulder Weekly - February 9th, 2017 [February 9th, 2017]
- Buy psychedelics online : Chinglabs.com - February 12th, 2017 [February 12th, 2017]
- Psychedelic drugs like magic mushrooms and LSD have key ... - Yahoo Finance - February 13th, 2017 [February 13th, 2017]
- Psychedelics a Viable Therapeutic Option for Depression - Psychiatry Advisor - February 14th, 2017 [February 14th, 2017]
- Is Silicon Valley Onto Something With Its LSD Microdosing? - Newsweek - February 15th, 2017 [February 15th, 2017]
- News Releases - Noozhawk - February 16th, 2017 [February 16th, 2017]
- A Revolution in the Science of Psychedelics is Happening in Boulder - 303 Magazine - February 16th, 2017 [February 16th, 2017]
- When Reality Is More Intense Than Psychedelics: Strand Of Oaks ... - NPR - February 17th, 2017 [February 17th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - AlterNet - February 22nd, 2017 [February 22nd, 2017]
- Psychedelics May Help Reduce Opioid Addiction, According To ... - Huffington Post - February 23rd, 2017 [February 23rd, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - eNews Park Forest - February 24th, 2017 [February 24th, 2017]
- Psychedelics Could Play A Role In Tackling The Opioid Epidemic - Huffington Post - February 24th, 2017 [February 24th, 2017]
- Meet The People's Champion of Psychedelic Drugs - Narratively - February 27th, 2017 [February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way ... - Yahoo Finance - February 27th, 2017 [February 27th, 2017]
- First U. student group on studying psychedelics holds open house - The Daily Princetonian - February 27th, 2017 [February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way people see the world - Businessinsider India - February 28th, 2017 [February 28th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New ... - February 28th, 2017 [February 28th, 2017]
- WATCH: A Public Policy Expert Explains How to Safely Deregulate LSD and Other Psychedelics - AlterNet - March 7th, 2017 [March 7th, 2017]
- Quotes About Psychedelics (48 quotes) - March 7th, 2017 [March 7th, 2017]
- Inside the Psychedelic Underground - RollingStone.com - March 9th, 2017 [March 9th, 2017]
- What Psychedelics Really Do to Your Brain - Rolling Stone - RollingStone.com - March 10th, 2017 [March 10th, 2017]
- Hallucinogens Help, According to a Mom's Memoir and Son's Documentary - Bedford + Bowery - April 8th, 2017 [April 8th, 2017]
- Meditation and the psychedelic drug ayahuasca seem to change the brain in surprisingly similar ways - Businessinsider India - April 8th, 2017 [April 8th, 2017]
- Tripping out: the highs and lows of psychedelic therapy - Marie Claire UK - April 8th, 2017 [April 8th, 2017]
- Stop Policing Psychedelic Science - Motherboard - June 6th, 2017 [June 6th, 2017]
- America's Trippiest Chemist: Making Psychedelics 'Was Fun' - Motherboard - June 6th, 2017 [June 6th, 2017]
- The Three Types of Hallucinogens: Psychedelics ... - June 7th, 2017 [June 7th, 2017]
- Cary Grant was one of the first to benefit from LSD therapy - Quartz - June 11th, 2017 [June 11th, 2017]
- What it's like to take psychedelics in small doses at breakfast - New Scientist - June 14th, 2017 [June 14th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - Religion News Service - June 14th, 2017 [June 14th, 2017]
- Q&A With Psychedelic Stand-Up and LaughFest Headliner Shane Mauss - Flagpole Magazine - June 20th, 2017 [June 20th, 2017]
- Q&A: LaughFest comedian talks science and psychedelics - Red and Black - June 20th, 2017 [June 20th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Daily Tribune - June 21st, 2017 [June 21st, 2017]
- Shane Mauss brings Good Trip Comedy Tour to town - Chattanooga Times Free Press - June 22nd, 2017 [June 22nd, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Oakland Press - June 22nd, 2017 [June 22nd, 2017]
- Director Ana Lily Amirpour on Cannibalism, Psychedelics, and 'Horrifying' Racism Allegations - Jezebel - June 23rd, 2017 [June 23rd, 2017]
- Majority of Americans ready to embrace psychedelic therapy - YouGov US - June 24th, 2017 [June 24th, 2017]
- The Refugee Funding America's Psychedelic Renaissance - VICE - June 24th, 2017 [June 24th, 2017]
- Open Your Mind This Weekend at Europe's Largest Psychedelic Conference - VolteFace Magazine (blog) - June 27th, 2017 [June 27th, 2017]
- Psychedelics and Virtual Reality Make a Trendy but Illegal Therapy - Inverse - June 27th, 2017 [June 27th, 2017]
- The war on drugs is back. Will psychedelic drug research survive? - The Verge - June 29th, 2017 [June 29th, 2017]
- Tune in, Turn on, Stay in School - Study Breaks - July 2nd, 2017 [July 2nd, 2017]
- Cannabist Show: He's psychedelic comedian Shane Mauss - The Cannabist - July 2nd, 2017 [July 2nd, 2017]
- The brain on DMT: mapping the psychedelic drug's effects - Wired.co.uk - July 3rd, 2017 [July 3rd, 2017]
- Psychedelics Could Help Asia's Mental Health Care, But Stigma Remains Roadblock - TheFix.com - July 3rd, 2017 [July 3rd, 2017]
- Is LSD the new coffee? - FactorDaily - July 4th, 2017 [July 4th, 2017]
- My grandfather was a death row doctor. He tested psychedelic drugs on Texas inmates. - Texas Tribune - July 5th, 2017 [July 5th, 2017]
- About Us | Trusted News Source for Psychedelic Research ... - July 6th, 2017 [July 6th, 2017]
- Do Psychedelic Drugs Cause the 'Prophetic Effect'? - Breaking Israel News - July 11th, 2017 [July 11th, 2017]
- Are psychedelics the new medical marijuana? - WTSP 10 News - July 14th, 2017 [July 14th, 2017]
- Psychiatrists Say Cannabis Medicine Has Psychedelic Properties - The Marijuana Times - July 15th, 2017 [July 15th, 2017]
- Can Psychedelics Be Therapy? Allow Research to Find Out - New York Times - July 17th, 2017 [July 17th, 2017]
- Countdown To (Legalized) Ecstasy! Rick Doblin, MAPS, & the Psychedelic Renaissance [Podcast] - Reason (blog) - July 20th, 2017 [July 20th, 2017]
- Should We Reclassify Marijuana as a Hallucinogen? - Big Think - July 20th, 2017 [July 20th, 2017]
- Do You Take Drugs at Festivals? This Initiative is Working on Keeping You Safe - PoliticalCritique.org - July 20th, 2017 [July 20th, 2017]
- Psychedelic drugs could tackle depression in a way that antidepressants can't - INSIDER - July 22nd, 2017 [July 22nd, 2017]
- Psychedelic Shine takes a trip to the skies in Boulder - Boulder Daily Camera - July 22nd, 2017 [July 22nd, 2017]
- Reasons to Consider Trying Psychedelics - FoxWeekly - July 27th, 2017 [July 27th, 2017]
- Psychedelics and Normality - HuffPost - July 27th, 2017 [July 27th, 2017]
- New book about psychedelics and weird human experiences - Boing Boing - July 27th, 2017 [July 27th, 2017]
- Scientists Want You to Give Them Money to Study ... - July 29th, 2017 [July 29th, 2017]
- What Has Awe Done for Me Lately? - HuffPost - August 1st, 2017 [August 1st, 2017]
- For children, it's beyond psychedelics - The Hans India - The Hans India - August 1st, 2017 [August 1st, 2017]
- Expanding consciousness - 48 Hills - August 2nd, 2017 [August 2nd, 2017]
- THE FUTURE OF PSYCHEDELICS: Are LSD and Mushrooms The New Prozac? - Dope Magazine - August 5th, 2017 [August 5th, 2017]
- Psychedelic drugs saved my life. So why aren't they prescribed? - Wired.co.uk - August 9th, 2017 [August 9th, 2017]
- LSD as therapy: How scientists are reclaiming psychedelics ... - August 9th, 2017 [August 9th, 2017]
- The foundation of Western philosophy is probably rooted in psychedelics - Quartz - August 12th, 2017 [August 12th, 2017]
- Crazy Enough to be Correct - HuffPost - August 15th, 2017 [August 15th, 2017]